- Home
- SAVA vs GECC Comparison
SAVA vs GECC Comparison
Compare SAVA & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- GECC
- Stock Information
- Founded
- SAVA 1998
- GECC 2016
- Country
- SAVA United States
- GECC United States
- Employees
- SAVA N/A
- GECC N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- GECC Finance: Consumer Services
- Sector
- SAVA Health Care
- GECC Finance
- Exchange
- SAVA Nasdaq
- GECC Nasdaq
- Market Cap
- SAVA 157.5M
- GECC 127.9M
- IPO Year
- SAVA N/A
- GECC N/A
- Fundamental
- Price
- SAVA $2.82
- GECC $7.55
- Analyst Decision
- SAVA Buy
- GECC Buy
- Analyst Count
- SAVA 2
- GECC 2
- Target Price
- SAVA $5.00
- GECC $10.75
- AVG Volume (30 Days)
- SAVA 1.2M
- GECC 121.5K
- Earning Date
- SAVA 11-12-2025
- GECC 11-04-2025
- Dividend Yield
- SAVA N/A
- GECC 20.39%
- EPS Growth
- SAVA N/A
- GECC N/A
- EPS
- SAVA N/A
- GECC N/A
- Revenue
- SAVA N/A
- GECC $46,553,000.00
- Revenue This Year
- SAVA N/A
- GECC $30.29
- Revenue Next Year
- SAVA N/A
- GECC N/A
- P/E Ratio
- SAVA N/A
- GECC N/A
- Revenue Growth
- SAVA N/A
- GECC 17.68
- 52 Week Low
- SAVA $1.15
- GECC $7.18
- 52 Week High
- SAVA $33.98
- GECC $11.46
- Technical
- Relative Strength Index (RSI)
- SAVA 38.79
- GECC 37.24
- Support Level
- SAVA $2.65
- GECC $7.30
- Resistance Level
- SAVA $3.30
- GECC $7.90
- Average True Range (ATR)
- SAVA 0.21
- GECC 0.32
- MACD
- SAVA -0.07
- GECC 0.06
- Stochastic Oscillator
- SAVA 18.02
- GECC 16.39
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.